SSRI/SNRI Pregnancy Exposure Risks Should Be In Patient Labeling, Pediatric Subcmte. Says

Subcommittee rejects public health advisory on selective serotonin re-uptake inhibitor withdrawal syndrome risks to newborns. FDA is preparing class labeling that will add precautions to pregnancy section of SSRI/SNRIs.